TrialJournal for immunotherapy of cancer2021

IL-7 expands lymphocyte populations and enhances immune responses to sipuleucel-T in patients with metastatic castration-resistant prostate cancer (mCRPC).

Russell K Pachynski et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.